Nagi Bioscience
in vivo testing at the in vitro scale
in vivo testing at the in vitro scale
Nagi Bioscience is a Swiss-based biotechnology startup founded in 2019. The company's slogan "in vivo testing at the in vitro scale" summarizes its pioneering work in developing NextGen laboratory equipment to facilitate alternatives to animal testing. This cutting-edge technology aims to accelerate drug development pipelines and set new standards in toxicology testing within pharmaceutical, cosmetic, and agro-chemical industries. The recent Fr.12.40M Series A investment at 28 September 2023 attracted backing from notable investors including Verve Ventures, Imec.xpand, Swisscanto Invest, Excellis, and Zürcher Kantonal Bank. Nagi Bioscience's focus on leveraging small organisms for high-content screening of substances signals its commitment to ethical and efficient biological testing standards, positioning the company at the forefront of the industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Fr.12.40M | 5 |
|
28 Sep 2023 |
| Grant | €2.50M | 1 |
|
21 Mar 2022 |
| Seed Round | Fr.1.80M | 3 |
|
20 Dec 2019 |
| Pre Seed Round | Fr.100.00K | 1 |
|
16 Jan 2019 |
| Grant | Fr.20.00K | 1 |
|
27 Jun 2018 |
No recent news or press coverage available for Nagi Bioscience.
We care about your data, and we'd love to use cookies make your experience better.
